FDA approves first treatment for certain types of poor-prognosis acute myeloid leukemia

By Newsroom America Feeds at 3 Aug 2017

The U.S. Food and Drug Administration today approved Vyxeos for the treatment of adults with two types of acute myeloid leukemia (AML): newly diagnosed therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC). Vyxeos is a fixed-combination of chemotherapy drugs daunorubicin and cytarabine.

https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm569883.htm

Categories:
Tags:

[D] [Digg] [FB] [R] [SU] [Tweet] [G]

NEWSMAIL